Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29752180 | 1.00 | CHEK1 (0.55) | CHEK1TLR7IRAK4NPC1RAB9A | |
| Formic Acid SCHEMBL18169747 | 0.96 | CHEK1 (0.52) | CHEK1TLR7IRAK4NPC1RAB9A | |
| Formic Acid SCHEMBL29687272 | 0.96 | CHEK1 (0.52) | CHEK1TLR7IRAK4NPC1RAB9A | |
| SCHEMBL18169641 | 0.85 | CHEK1 (0.54) | CHEK1TLR7IRAK4NPC1RAB9A | |
| SCHEMBL29610051 | 0.83 | CHEK1 (0.52) | CHEK1TLR7IRAK4NPC1RAB9A | |
| SCHEMBL29611087 | 0.83 | CHEK1 (0.52) | CHEK1TLR7IRAK4NPC1RAB9A | |
| SCHEMBL18169623 | 0.83 | CHEK1 (0.52) | CHEK1TLR7IRAK4NPC1RAB9A | |
| SCHEMBL18169783 | 0.83 | CHEK1 (0.52) | CHEK1TLR7IRAK4NPC1RAB9A | |
| SCHEMBL18169987 | 0.82 | CHEK1 (0.53) | CHEK1TLR7IRAK4PIM1 | |
| SCHEMBL29611065 | 0.82 | CHEK1 (0.53) | CHEK1TLR7IRAK4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | RIGEL PHARMACEUTICALS INC (US) | 2024-11-21 | — | — | US | claimed |
| US-20220249475-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | claimed |
| CN-113750094-A | Pyrazole compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2021-12-07 | — | — | CN | claimed |
| CN-107438603-B | Pyrazole compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2021-08-10 | — | — | CN | claimed |
| EP-3286181-B1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2021-01-27 | — | — | EP | claimed |
| EP-3286181-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | claimed |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | US | claimed |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | RIGEL PHARMACEUTICALS INC (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4399208-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | Rigel Pharmaceuticals, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023038815-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20220289776-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| EP-3286181-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | CHEK1 372/4885TLR7 114/4885IRAK4 4/4885 |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | CHEK1 414/4885TLR7 103/4885IRAK4 4/4885 |
| US-20220249475-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | IRAK1, IRAK3, IRAK2 | CHEK1 403/4885TLR7 32/4885IRAK4 4/4885 |
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | IRAK1, IRAK4, IRAK2 | CHEK1 1571/4885TLR7 8/4885IRAK4 2/4885 |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | CHEK1 414/4885TLR7 103/4885IRAK4 4/4885 |
| US-20220289776-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | CHEK1 372/4885TLR7 114/4885IRAK4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.